Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia

NEXT STORY
DSS BioHealth Security, Inc. Announces the Addition of Mr. Daryl Thompson and Dr. Roscoe Moore to Advisory Team
PREV STORY
Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck

author_avatar
NASDAQ Market News

BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors

author_avatar
NASDAQ Market News

G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. a ...

author_avatar
NASDAQ Market News